Amarin, Celgene, GlaxoSmithKline, Spectrum Pharma, and Geron Briefing and Review

LONDON, March 18, 2013 /PRNewswire/ --

The healthcare industry is evaluating the impact of President Obama's Affordable Care Act (ACA) on their businesses. While critics of the healthcare reform say that the ACA will result in higher costs for healthcare companies, supporters of the reform point out the long-term benefits to the industry which include players such as Amarin Corporation Plc (NASDAQ: AMRN), Celgene Corporation (NASDAQ: CELG), GlaxoSmithKline Plc (NYSE: GSK), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) and Geron Corporation (NASDAQ: GERN). On Friday, healthcare stocks ended mostly lower, tracking losses in the broad market. StockCall has released free charting and technical research on these aforementioned companies. Register to read these reports at  

Shares of Amarin Corporation Plc edged higher in Friday's trading session even as the broad market struggled. The stock closed 0.83% higher at $8.46 on volume of 2.40 million. Despite Friday's gains, Amarin's shares have fallen 2.08%. Year-to-date, the company's shares have gained more than 4.50%. The stock has just crossed its 50-day moving average, which is a bullish signal. The bullish trend is further confirmed by the MACD chart. The stock's MACD has just moved above the zero-line. Sign up for the free report on AMRN at  

Celgene Corporation shares fell sharply in trading on Friday. The stock closed 1.65% lower at $112.40 on above average volume of 4.97 million, paring most of the gains for the week. Still, the stock managed to finish almost 1% higher for the week. Celgence's shares have seen a series of highs over the last two weeks, which is a bullish signal. The positive trend is further confirmed by recent volume activity. However, the stock's MACD chart suggests that the upbeat trend may have come to an end. CELG free technical report can be accessed by signing up at  

Shares of U.K.-based pharmaceutical giant, GlaxoSmithKline Plc edged higher in trading on the previous week's last day trading session, extending its gains for the week. The stock finished 0.18% higher at $45.30 on volume of 1.99 million, taking its gains for the week to over 1.60%. GlaxoSmithKline's shares are facing stiff resistance at around $45.50. The stock has struggled to break through this level recently. The stock's MACD has just crossed above the signal line, which is a strong bullish signal. This optimistic trend is further confirmed by the volume activity in the last 10 sessions. Free report on GSK can be accessed by registering at  

Spectrum Pharmaceuticals Inc. shares have fallen sharply so far in 2013. Year-to-date, shares of the biotechnology company are down more than 30%, mainly due to the significant losses posted last week. Spectrum's shares fell more than 34% last week. On Friday, the stock once again struggled, falling 0.64% to finish the day at $7.76 on above average volume of 2.65 million. The company's shares have fallen below some key technical levels as a result of the sell-off last week.  Register with StockCall and download the research on SPPI for free at

Shares of Geron Corporation tumbled in Friday's trading session, ending 9.60% lower at $1.13 on above average volume of 2.89 million. The stock has now fallen more than 20% in the last three sessions. For the year, the stock is now down nearly 20%, mainly due to the losses seen a week ago. Geron's shares have fallen below $1.20 support level. The stock's MACD has also slipped below the signal line, which is a strong bearish signal. Read the full free research on GERN by signing up to StockCall at  

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at